Moleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026
Go back to Moleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026| METABASIS THERAPEUT (NASDAQ: MBRX) | Delayed: 2.88 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.88 | 52 Week High | $9.58 | |||
| Open | $2.88 | 52 Week Low | $2.34 | |||
| Day High | $2.88 | P/E | N/A | |||
| Day Low | $2.88 | EPS | $-0.34 | |||
| Volume | 29,425 | |||||
